%0 Journal Article
%T Decitabine treatment sensitizes tumor cells to T-cell-mediated cytotoxicity in patients with myelodysplastic syndromes
%A Chao Xiao
%A Chun-Kang Chang
%A Dong Wu
%A Feng Xu
%A Ji-Ying Su
%A Juan Guo
%A Li-Yu Zhou
%A Ling-Yun Wu
%A Lu-Xi Song
%A Qi He
%A Xiao Li
%A Ying Tao
%A You-Shan Zhao
%A Zheng Zhang
%J Archive of "American Journal of Translational Research".
%D 2017
%X Decitabine treatment improves immunological recognition that increases expression of cancer-testis antigens (CTAs) against solid tumors. The mechanisms of decitabine enhancement of immunogenicity when used for patients with myelodysplastic syndromes (MDS) remain unclear. In the present study, we found relatively low baseline expression of MAGE-A1, MAGE-A3, and SP17 in MDS-derived cell lines. Decitabine treatment significantly improved MAGE-A1, MAGE-A3, and SP17 expression in these cell lines and in MDS patients. Decitabine-treated K562 and SKM-1 target cells with incrementally induced MAGE-A1, MAGE-A3, or SP17 levels up-regulated T lymphocyte function. Decitabine treatment improved CTA-specific cytotoxic T lymphocyte (CTL) recognition of MDS cells via the up-regulation of CTAs. This response was accompanied by enhanced T lymphocyte function and HLA class antigen expression, and increased ICAM-1. These findings suggested that decitabine may have a broad range of therapeutic applications when it is used in association with active adaptive immunity responses against up-regulated CTAs
%K Myelodysplastic syndromes
%K decitabine
%K T cytotoxicity
%K cancer-testis antigens
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340681/